Stem definition | Drug id | CAS RN |
---|---|---|
949 | 120279-96-1 |
Dose | Unit | Route |
---|---|---|
0.30 | ml | None |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 3.90 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 10 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 3.08 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Date | Agency | Company | Orphan |
---|---|---|---|
Dec. 9, 1994 | FDA | MERCK |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Eye irritation | 509.48 | 51.89 | 92 | 604 | 3420 | 2353969 |
Intraocular pressure increased | 341.88 | 51.89 | 58 | 638 | 1451 | 2355938 |
Ocular hyperaemia | 209.01 | 51.89 | 45 | 651 | 4011 | 2353378 |
Eye pain | 189.69 | 51.89 | 43 | 653 | 4848 | 2352541 |
Drug ineffective | 181.01 | 51.89 | 85 | 611 | 101539 | 2255850 |
Product quality issue | 174.50 | 51.89 | 47 | 649 | 10782 | 2346607 |
Glaucoma | 134.89 | 51.89 | 28 | 668 | 2067 | 2355322 |
Vision blurred | 100.78 | 51.89 | 33 | 663 | 14635 | 2342754 |
No adverse event | 92.77 | 51.89 | 28 | 668 | 9500 | 2347889 |
Visual acuity reduced | 85.00 | 51.89 | 23 | 673 | 5275 | 2352114 |
Eye pruritus | 75.28 | 51.89 | 18 | 678 | 2513 | 2354876 |
Product dose omission | 73.17 | 51.89 | 34 | 662 | 38223 | 2319166 |
Hand deformity | 72.61 | 51.89 | 15 | 681 | 1071 | 2356318 |
Eye discharge | 69.07 | 51.89 | 14 | 682 | 909 | 2356480 |
Ocular surface disease | 66.43 | 51.89 | 8 | 688 | 10 | 2357379 |
Dyspnoea | 62.61 | 51.89 | 39 | 657 | 78694 | 2278695 |
Sciatica | 62.59 | 51.89 | 15 | 681 | 2110 | 2355279 |
Eye swelling | 60.83 | 51.89 | 17 | 679 | 4373 | 2353016 |
Product packaging quantity issue | 54.55 | 51.89 | 10 | 686 | 380 | 2357009 |
Choroidal detachment | 54.31 | 51.89 | 8 | 688 | 74 | 2357315 |
Drug hypersensitivity | 52.50 | 51.89 | 29 | 667 | 46614 | 2310775 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Intraocular pressure increased | 339.01 | 69.84 | 57 | 452 | 1124 | 1745148 |
Eye irritation | 295.28 | 69.84 | 52 | 457 | 1351 | 1744921 |
Ocular hyperaemia | 148.23 | 69.84 | 31 | 478 | 1979 | 1744293 |
Eye pain | 132.40 | 69.84 | 29 | 480 | 2302 | 1743970 |
Visual acuity reduced | 97.62 | 69.84 | 25 | 484 | 3863 | 1742409 |
Product quality issue | 86.49 | 69.84 | 25 | 484 | 6068 | 1740204 |
Eye pruritus | 79.44 | 69.84 | 16 | 493 | 834 | 1745438 |
Drug ineffective | 77.00 | 69.84 | 44 | 465 | 63757 | 1682515 |
Source | Code | Description |
---|---|---|
ATC | S01EC03 | SENSORY ORGANS OPHTHALMOLOGICALS ANTIGLAUCOMA PREPARATIONS AND MIOTICS Carbonic anhydrase inhibitors |
CHEBI has role | CHEBI:35674 | antihypertensive agent |
CHEBI has role | CHEBI:39456 | antiglaucoma drug |
MeSH PA | D000959 | Antihypertensive Agents |
MeSH PA | D002257 | Carbonic Anhydrase Inhibitors |
MeSH PA | D002317 | Cardiovascular Agents |
MeSH PA | D004791 | Enzyme Inhibitors |
FDA EPC | N0000175517 | Carbonic Anhydrase Inhibitor |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Ocular hypertension | indication | 4210003 | DOID:9282 |
Open-angle glaucoma | indication | 84494001 | DOID:1067 |
Bronchospasm | contraindication | 4386001 | |
Complete atrioventricular block | contraindication | 27885002 | |
Acute cerebrovascular insufficiency | contraindication | 29322000 | |
Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
Anaphylaxis | contraindication | 39579001 | |
Sinus bradycardia | contraindication | 49710005 | |
General anesthesia | contraindication | 50697003 | |
Acute nephropathy | contraindication | 58574008 | |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Pulmonary emphysema | contraindication | 87433001 | |
Cardiogenic shock | contraindication | 89138009 | |
Myasthenia gravis | contraindication | 91637004 | DOID:437 |
Partial atrioventricular block | contraindication | 195039008 | |
Decompensated cardiac failure | contraindication | 195111005 | |
Hypoglycemic disorder | contraindication | 237630007 | |
Pregnancy, function | contraindication | 289908002 | |
Severe chronic obstructive pulmonary disease | contraindication | 313299006 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 7.73 | acidic |
pKa2 | 8.34 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Carbonic anhydrase 2 | Enzyme | INHIBITOR | Ki | 9.70 | CHEMBL | CHEMBL | |||
Carbonic anhydrase 12 | Enzyme | Ki | 8.46 | CHEMBL | |||||
Carbonic anhydrase 4 | Enzyme | Ki | 7.37 | CHEMBL | |||||
Carbonic anhydrase 13 | Enzyme | Ki | 7.74 | CHEMBL | |||||
Carbonic anhydrase 3 | Enzyme | Ki | 5.10 | CHEMBL | |||||
Carbonic anhydrase 5A, mitochondrial | Enzyme | Ki | 7.38 | CHEMBL | |||||
Carbonic anhydrase 14 | Enzyme | Ki | 7.57 | CHEMBL | |||||
Carbonic anhydrase 7 | Enzyme | Ki | 8.46 | CHEMBL | |||||
Carbonic anhydrase 9 | Enzyme | Ki | 7.28 | CHEMBL | |||||
Carbonic anhydrase 1 | Enzyme | Ki | 6.30 | CHEMBL | |||||
Carbonic anhydrase 5B, mitochondrial | Enzyme | Ki | 7.48 | CHEMBL | |||||
Carbonic anhydrase 6 | Enzyme | Ki | 8 | CHEMBL | |||||
Carbonic anhydrase 13 | Enzyme | Ki | 7.74 | CHEMBL | |||||
Carbonic anhydrase | Enzyme | Ki | 4.51 | CHEMBL | |||||
Alpha carbonic anhydrase | Unclassified | Ki | 7.74 | CHEMBL | |||||
Probable transmembrane carbonic anhydrase (Carbonate dehydratase) (Carbonic dehydratase); Transmembrane carbonic anhydrase | Enzyme | Ki | 6.86 | CHEMBL | |||||
Astrosclerin-3 | Unclassified | Ki | 6.55 | CHEMBL | |||||
Beta-carbonic anhydrase 1 | Enzyme | Ki | 6.13 | CHEMBL | |||||
Carbonic anhydrase | Unclassified | Ki | 6.95 | CHEMBL | |||||
Delta carbonic anhydrase | Unclassified | Ki | 7.30 | CHEMBL | |||||
Carbonic anhydrase | Enzyme | Ki | 6.96 | CHEMBL | |||||
Carbonic anhydrase | Enzyme | Ki | 5.37 | CHEMBL | |||||
Carbonic anhydrase 15 | Enzyme | Ki | 7.21 | CHEMBL | |||||
Carbonic anhydrase | Enzyme | Ki | 8.05 | CHEMBL | |||||
Carbonic anhydrase | Enzyme | Ki | 6.39 | CHEMBL | |||||
Carbonic anhydrase 2 | Enzyme | Ki | 7 | CHEMBL | |||||
Carbonic anhydrase 4 | Enzyme | Ki | 7.37 | CHEMBL | |||||
Carbonic anhydrase | Unclassified | Ki | 6.56 | CHEMBL | |||||
Carbonic anhydrase | Enzyme | Ki | 5.18 | CHEMBL |
ID | Source |
---|---|
4023982 | VUID |
N0000021987 | NUI |
C0165590 | UMLSCUI |
D00653 | KEGG_DRUG |
108834004 | SNOMEDCT_US |
4023982 | VANDF |
60207 | RXNORM |
373447009 | SNOMEDCT_US |
004998 | NDDF |
9JDX055TW1 | UNII |
6960 | INN_ID |
CHEMBL218490 | ChEMBL_ID |
DB00869 | DRUGBANK_ID |
130693-82-2 | SECONDARY_CAS_RN |
ETS | PDB_CHEM_ID |
CHEBI:4702 | CHEBI |
6810 | IUPHAR_LIGAND_ID |
5284549 | PUBCHEM_CID |
CHEMBL1201162 | ChEMBL_ID |
C062765 | MESH_SUPPLEMENTAL_RECORD_UI |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
TRUSOPT | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0006-3519 | SOLUTION | 20 mg | OPHTHALMIC | NDA | 18 sections |
Dorzolamide Hydrochloride-Timolol Maleate | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0527-1763 | SOLUTION | 20 mg | OPHTHALMIC | ANDA | 13 sections |
Dorzolamide HCl and Timolol Maleate | HUMAN PRESCRIPTION DRUG LABEL | 2 | 17478-514 | SOLUTION/ DROPS | 20 mg | OPHTHALMIC | ANDA | 18 sections |
COSOPT PF | HUMAN PRESCRIPTION DRUG LABEL | 2 | 17478-604 | SOLUTION/ DROPS | 20 mg | OPHTHALMIC | NDA | 18 sections |
COSOPT | HUMAN PRESCRIPTION DRUG LABEL | 2 | 17478-605 | SOLUTION/ DROPS | 20 mg | OPHTHALMIC | NDA | 17 sections |
Dorzolamide HCl | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24208-485 | SOLUTION/ DROPS | 20 mg | OPHTHALMIC | ANDA | 18 sections |
Dorzolamide Hydrochloride and Timolol Maleate | HUMAN PRESCRIPTION DRUG LABEL | 2 | 24208-486 | SOLUTION/ DROPS | 20 mg | OPHTHALMIC | ANDA | 17 sections |
Dorzolamide Hydrochloride Ophthalmic Solution | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42571-141 | SOLUTION/ DROPS | 20 mg | OPHTHALMIC | ANDA | 17 sections |
Dorzolamide Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-1246 | SOLUTION/ DROPS | 20 mg | OPHTHALMIC | ANDA | 16 sections |
Dorzolamide Hydrochloride and Timolol Maleate | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50090-1247 | SOLUTION/ DROPS | 20 mg | OPHTHALMIC | ANDA | 16 sections |
Dorzolamide HCl | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-2406 | SOLUTION/ DROPS | 20 mg | OPHTHALMIC | ANDA | 18 sections |
Dorzolamide HCl | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-2768 | SOLUTION | 20 mg | OPHTHALMIC | ANDA | 17 sections |
Dorzolamide HCl and Timolol Maleate | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50090-2867 | SOLUTION | 20 mg | OPHTHALMIC | ANDA | 18 sections |
Dorzolamide Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50383-232 | SOLUTION/ DROPS | 20 mg | OPHTHALMIC | ANDA | 16 sections |
Dorzolamide Hydrochloride and Timolol Maleate | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50383-233 | SOLUTION/ DROPS | 20 mg | OPHTHALMIC | ANDA | 16 sections |
Dorzolamide Hydrochloride and Timolol Maleate | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50383-261 | SOLUTION/ DROPS | 20 mg | OPHTHALMIC | NDA | 17 sections |
Cosopt | HUMAN PRESCRIPTION DRUG LABEL | 2 | 54868-4279 | SOLUTION | 20 mg | OPHTHALMIC | NDA | 13 sections |
Dorzolamide Hydrochloride and Timolol Maleate | HUMAN PRESCRIPTION DRUG LABEL | 2 | 54868-5982 | SOLUTION/ DROPS | 20 mg | OPHTHALMIC | ANDA | 14 sections |
Dorzolamide HCl | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-6330 | SOLUTION/ DROPS | 22.30 mg | OPHTHALMIC | ANDA | 13 sections |
Dorzolamide and Timolol | HUMAN PRESCRIPTION DRUG LABEL | 2 | 55545-1007 | SOLUTION | 20 mg | OPHTHALMIC | ANDA | 1 sections |
Dorzolamide hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55545-1008 | SOLUTION | 20 mg | OPHTHALMIC | ANDA | 1 sections |
Dorzolamide Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60429-114 | SOLUTION/ DROPS | 20 mg | OPHTHALMIC | ANDA | 16 sections |
Dorzolamide Hydrochloride and Timolol Maleate | HUMAN PRESCRIPTION DRUG LABEL | 2 | 60429-115 | SOLUTION/ DROPS | 20 mg | OPHTHALMIC | ANDA | 16 sections |
DORZOLAMIDE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 61314-019 | SOLUTION/ DROPS | 20 mg | OPHTHALMIC | ANDA | 17 sections |
Dorzolamide Hydrochloride and Timolol Maleate | HUMAN PRESCRIPTION DRUG LABEL | 2 | 61314-030 | SOLUTION | 20 mg | OPHTHALMIC | ANDA | 17 sections |
Dorzolamide Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62332-519 | SOLUTION/ DROPS | 20 mg | OPHTHALMIC | ANDA | 17 sections |
Dorzolamide Hydrochloride and Timolol Maleate Preservative Free | HUMAN PRESCRIPTION DRUG LABEL | 2 | 65862-947 | SOLUTION/ DROPS | 20 mg | OPHTHALMIC | ANDA | 17 sections |
Dorzolamide hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69315-304 | SOLUTION | 20 mg | OPHTHALMIC | ANDA | 16 sections |
Dorzolamide and Timolol | HUMAN PRESCRIPTION DRUG LABEL | 2 | 69315-305 | SOLUTION | 20 mg | OPHTHALMIC | ANDA | 16 sections |
DORZOLAMIDE HYDROCHLORIDE and TIMOLOL MALEATE | HUMAN PRESCRIPTION DRUG LABEL | 2 | 70069-051 | SOLUTION | 20 mg | OPHTHALMIC | ANDA | 16 sections |